Dimethyl fiimarate: A fumaric acid ester under investigation for the treatment of relapsing-remitting multiple sclerosis

Formulary

Volumn 47, Issue 11, 2012, Pages 386-389

  Sobieraj, Diana M ^a   Coleman, Craig I ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMADERM; FUMARIC ACID DIMETHYL ESTER; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DIARRHEA; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MULTIPLE SCLEROSIS; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN;

EID: 84869803257     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Neurological disorders: A public health approach. In: Neurobgical Disorders: Public Health Challenges. World Health Organization. Geneva, Switzerland: WHO Press; 2007. http://www.who.int/mental_health/neurology/neurodiso/en/index.html. Accessed September 12,2012.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46:907-911.
4. Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-178.
5. Drugs@FDA. Gilenya (fingolimod) package insert. Basel, Switzerland: Novartis; revised May 2012. http://www.accessdata.fda.gov/drugsatf-da_docs/label/2012/022527s0081bl.pdf. Accessed September 12,2012.
6. FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm. Accessed September 12,2012.
7. Fox RJ. BG-00012-A novel oral therapy in development for the treatment of multiple sclerosis. Eur Neurol Rev. 2008;3:100-103.
8. Papadopoulou A, D'Souza M, Kappos L, Yaldizli O. Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs. 2010;19:1603-1612.
9. Adis R&D profile. BG 12: BG 00012, BG 12/ oral fumarate, FAG-201, second-generation fumarate derivative-Fumapharm/Biogen Idee. Drug RD. 2005;6:229-230.
10. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2012; 25 Suppl: Sll-S19.
11. Lukashev M, Zeng W, Goelz S, et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Abstract P503. Mult Scler. 2007;13(2 Suppl):S149.
12. Asadullah K, Schmid H, Friedrich M, et al. Influence of monomethylfumarate on monocytic cytokine formation-Explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res. 1997;289:623-630.
13. de Jong R, Bezemer AC, Zomerdijk TP, et al. Selective stimulation of T helper 2 cytokine response by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26:2067-2074.
14. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145:101-107.
15. Li J, Johnson D, Calkins M, et al. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. ToxicolSci. 2005;83:313-328.
16. Satoh T, Okamoto SI, Cui J, et al. Activation of the Keapl/Nrf2 pathway for neuroprotection by electrophilic phase II inducers. Proc Natl Acad Sci USA. 2006;103:768-773.
17. Vargas MR, Pehar M, Cassina P, et al. Fibroblast growth factor-1 induces heme oxygen-ase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: Consequences for motor neuron survival. J Biol Chem. 2005;280:25571-25579.
18. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003;24:259-273.
19. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol. 1999;141:424-429.
20. Litjens NH, Burggraaf J, van Strijen E, et al. Pharmacokinetics of oral fumarates in healthy subjects. BrJ Clin Pharmacol. 2004;58:429-432.
21. Kappos L, Gold R, Miller DH, et al; BG-12 Phase lib Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase lib study. Lancet. 2008;372:1463-1472.
22. Fox R, Miller D, Phillips T, et al. Baseline characteristics of patients enrolled in a randomized, multicenter, placebo-controlled and active comparator trial evaluating efficacy and safety of BG-12 in relapsing-remitting multiple sclerosis: The CONFIRM trial. Abstract P06.158. Neurology. 2010;74(9 Suppl 2):A549.
23. Biogen Idee press release. Biogen Idee announces positive top-line results from second phase 3 trial investigating oral BG-12 (dimethyl fumarate) in multiple sclerosis. October 26, 2011. http://www.biogenidec.com/press_re-lease_details.aspx?ID=5981&ReqId=1621631. Accessed September 12, 2012.
24. Gold R, Arnold D, Kappos L, et al. Baseline characteristics of patients in the DEFINE trial: A randomized, multicenter, double-blind, placebo-controlled, randomized, phase 3 study of BG-12 in relapsing-remitting multiple sclerosis. Abstract P06.149. Neurology. 2010;74(9 Suppl 2):A546-A547.
25. Giovannoni G, Gold R, Kappos L, et al. BG-12 increases the proportion of patients free of clinical and radiologic disease activity in relapsing-remitting multiple sclerosis: Findings from the DEFINE study. Neurology. 2012; 78 (Meeting Abstracts 1): PD5.005. http://www.neurology.org/cgi/content/meeting_abstract/78/l_Meet-ingAbstracts/PD5.005. Accessed September 12, 2012.
26. Biogen Idee press release. Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE phase 3 clinical trial. October 21, 2011. http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqID=1619878. Accessed September 12, 2012.
27. ClinicalTrials.gov. Long-term safety and efficacy study of oral BG00012 monotherapy in relapsing-remitting multiple sclerosis. NCT00835770. www.clinicaltrials.gov/ct2/show/NCT00835770?term=BG-12&rank=5. Accessed September 12, 2012.
28. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121(Pt l):3-24.
29. Kappos L, Gold R, Miller DH, et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2b study. Mult Scler. 2012;18:314-321.
30. Phillips JT, Fox R, Miller D, et al. Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis (RRMS): Analyses from the CONFIRM study. Neurology. 2012; 78(Meeting Abstracts 1): S41.005. http://www.neurology.org/cgi/content/meeting_abstract/78/l_MeetingAbstracts/S41.005. Accessed September 12, 2012